J. Yale, G. Bakris, B. Cariou
Oct 1, 2014
Citations
11
Influential Citations
228
Citations
Quality indicators
Journal
Diabetes
Abstract
This study evaluated the efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and within a subset of Stage 3 chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] ≥30 and <50 ml/min/1.73 m2).